1. Home
  2. IDN vs CING Comparison

IDN vs CING Comparison

Compare IDN & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellicheck Inc.

IDN

Intellicheck Inc.

N/A

Current Price

$2.82

Market Cap

73.5M

Sector

Technology

ML Signal

N/A

CING

Cingulate Inc.

N/A

Current Price

$5.32

Market Cap

64.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IDN
CING
Founded
1994
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.5M
64.5M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
IDN
CING
Price
$2.82
$5.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$7.33
$34.50
AVG Volume (30 Days)
463.7K
146.1K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
220.00
56.47
EPS
0.06
N/A
Revenue
$4,433,454.00
N/A
Revenue This Year
$12.54
N/A
Revenue Next Year
$15.32
N/A
P/E Ratio
$47.33
N/A
Revenue Growth
23.21
N/A
52 Week Low
$2.70
$3.16
52 Week High
$9.08
$11.89

Technical Indicators

Market Signals
Indicator
IDN
CING
Relative Strength Index (RSI) 27.47 55.62
Support Level $2.70 $4.76
Resistance Level $4.49 $5.54
Average True Range (ATR) 0.16 0.31
MACD -0.03 0.02
Stochastic Oscillator 11.40 56.06

Price Performance

Historical Comparison
IDN
CING

About IDN Intellicheck Inc.

Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: